FAQ

Questions about the company

Q. Can you tell us the origin of the company name?

A. The founder establishedSNBL Co., Ltd. as Japan's first company to undertake experimental medical research related to the development of new drugs. As a healthcare company that is involved in the health of humankind, we want to grow on a scientific basis.

Q. Can you tell me about the company's history?

In 1957, the first president, Tsuguo Nagata, founded the company in Kagoshima City, and later, it began to undertake non-clinical trials of pharmaceuticals from major overseas pharmaceutical companies, growing into the first CRO in the country. For more details History Please see.

Q. Can you tell me about the corporate philosophy / the meaning of the logo?

A. Our corporate philosophy is to continue to be a company that values the environment, life, and human resources. This is entrusted to the three colors of theSNBL logo: blue, green and navy blue. The color blue refers to the environment, and it means to keep the blue sky, the blue sea, the wonderful earth, and the beautiful environment forever. Green symbolizes "life" and calls us to continue to be in awe of irreplaceable and precious life.
And, navy blue signifies 'human resources,' with a philosophy of valuing the 'heart' necessary for people to be valuable assets to society. For more details Here Please see.

Q. What kind of business do you conduct?

A. Based on the corporate philosophy of SNBL , we are currently developing three business areas with the aim of "creating a chain of happiness by being close to all stakeholders involved in our company."

1.
CRO business: This isSNBL 's flagship business. We conduct non-clinical studies and clinical trials (clinical trials) necessary for drug development on behalf of pharmaceutical companies. Companies that are contracted with testing by pharmaceutical companies are called CROs (Contract Research Organizations), and we are the first CRO in Japan.

2.
Translational Research (TR) Business: We support the discovery of promising seeds and new technologies from basic research at domestic and international universities and bio-ventures, enhancing their added value and facilitating their commercialization. Additionally, we are engaged in the development of formulations applying our independently developed intranasal administration platform technology.

3.
Social Benefit Creation Business: We are involved in the Medipolis business (hospitality and power generation businesses) as well as research and development for the artificial seed production of glass eels.

Questions regarding management and business

Q. What is your approach to corporate governance?

A. In order to further enhance corporate value, the basic policy of SNBL is to realize effective corporate governance by improving the soundness of management, improving efficiency, improving transparency, and strengthening the compliance system. For details Here Please see.

Q. What is SNBL 's commitment to sustainability?

A. Since its founding, SNBL has emphasized management centered on its corporate philosophy, and is proud to be a leading company in the industry in its ESG (Environment, Social, Governance) and SDGs (Sustainable Development Goals) initiatives. In particular, we have received the Prime Minister's Award and the Ministry of Health, Labour and Welfare Award as a company that excels in promoting women's empowerment, and in 2022 we were selected as a "Nadeshiko Brand" given by the Ministry of Economy, Trade and Industry. In addition, we have been selected as one of the White 500 Health & Productivity Management Outstanding Organizations for seven consecutive years, which is recognized as a company with an excellent track record in promoting health and productivity management. For details ESG introduction website Please see.

Q. When will eel be commercialized?

A. In recent years, due to fluctuations and surges in the catch and price of natural glass eels, there is a strong demand from the eel farming industry for a stable supply of glass eels.
Given that Kagoshima Prefecture has the largest share of eel farming in Japan, our company, headquartered in Kagoshima, considers it a social mission to contribute to the local community and protect biodiversity, and has started research on eel seed production. For more details Here (Eel page) Please see.

Questions regarding finance and performance

Q. When is the financial results announcement?

A. The fiscal year ends on March 31. The schedule and materials related to the financial results are Here Please see.

Q. Where can I check past financial information?

A. Our Financial Information Page Please see.

Q. Have you formulated a medium-term management plan?

A. Business Plan Please visit the page

Questions regarding stocks and dividends

Q. What is the stock ticker code?

A. The stock code for SNBL is 2395.

Q. I would like to know more details about dividends.

A. Regarding dividends, Here Please see.

Q. When is the shareholders' meeting scheduled?

A. The shareholders' meeting is held in late June every year. Here Please see the latest information regarding the shareholders' meeting.

Q. Where can I find the financial results briefing materials?

A. Regarding the financial-related materials, Here Please see.

Q. Where can I find the basic information about the stock?

A. Regarding the basic information about the stock, Here Please see.

Other questions

Q. Where can I find information about recruitment?

A. Recruitment page Here Please see.

Q. Could you tell me about the conferences you have participated in and the events you have held so far?

A. This SNBL IR PR Blog We are regularly sharing updates, so please take a look.

Q. Can individuals tour the facilities?

A. We apologize, but due to the need to maintain the high level of confidentiality required by our pharmaceutical company clients, as well as to protect our proprietary intellectual property and know-how, we do not offer facility tours for individuals.